Do you want patent numbers, expiration dates, or a general landscape for Novartis’s somatropin (Omnitrope) in a specific country or region?
Here’s a quick context you can use while we figure out the exact details:
- Somatropin is recombinant human growth hormone. The original r-hGH products (e.g., Humatrope) were developed in the 1980s, and the core protein/production patents from that era have expired in many jurisdictions, though there can be secondary patents on formulations, manufacturing processes, or methods of use that may still be in force in some places.
- Novartis’s somatropin biosimilar product is Omnitrope, marketed by Sandoz (Novartis). Omnitrope’s regulatory and patent history has involved navigating patents held by pioneer HGH developers (historically Genentech/Lilly) and various national patent offices.
- Patent status is jurisdiction-specific and can include active, expired, or lapsed patents, as well as a mix of core composition patents and process/formulation patents.
If you tell me:
- the country or region you care about (e.g., US, EU, UK, India, etc.), and
- whether you want (a) patent numbers, (b) expiry dates, or (c) a general overview,
I can pull together the current patent landscape for Novartis’s somatropin and provide sources (e.g., Espacenet, USPTO, WIPO, Google Patents) you can check for the latest status. I can also guide you on how to search for the relevant patent families (e.g., keywords like “somatropin,” “recombinant human growth hormone,” “Omnitrope,” “Sandoz,” and assignee names). Note: I’m not a lawyer; for enforceability and licensing questions, consult a patent attorney.